On Sunday in Chicago, Dr. Athena Philis-Tsimikas, vice president of San Diego’s Scripps Whittier Diabetes Institute in La Jolla, helped deliver positive news for the estimated 7 million Americans who ...

Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

CHICAGO — The investigational once-weekly basal insulin analog efsitora alfa lowered A1c as effectively as daily basal insulins in people with type 2 diabetes (T2D) who require insulin, showed three ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar ...

With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa. Lilly on Sunday ...